Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.

The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...

Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

Lilly answered with Mounjaro and Zepbound, approved in 2022 and 2023 for diabetes and weight loss, respectively. They use the ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...